±è¿ìÁØ(Kim Woo-Jun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç
Abstract
Since the discovery of specific antibody against aquaporin-4 (AQP4-Ab), the concept of the neuromyelitis optica (NMO) has been changed, and new findings about the disease have been exploded. This review covers clinical, pathological, immunological, and imaging studies published between 2012 and early 2013 that presented new findings on NMO. New rolls of AQP4-Abs, natural killer cells, cytotoxic T cells, eosinophils, and high-mobility group box 1 in the pathogenesis of NMO were presented. Studies using various imaging techniques, including voxel-wise analysis, double inversion recovery sequences, 7-tesla MRI, and MS spectroscopy, were published. The sensitivities and specificities of various AQP4-Ab tests were assessed, and the clinical characteristics of NMO patients who did not show seropositivity for AQP4-Ab were described. The efficacies of new therapeutics including plasmapheresis, several monoclonal antibodies, and other various medicines were also evaluated.
Å°¿öµå
Neuromyelitis optica, Neuromyelitis optica spectrum disorder, p Pathophysiology, Clinical Trai, Diagnosis Imaging, Treatment
KMID :
1022820140050010007
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)